2018 IPO

Guardant Health Stock

Bio-tech company focus on oncology

Sign up today and learn more about Guardant Health Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Sequoia Capital


Redwood City CA, US

Total Funding


About Guardant Health Stock

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.


Funding History

April 2013$9.2M
April 2014$32.6M
December 2014$56.0M
December 2015$83.9M
May 2017$334M


Chief Executive Officer

Helmy Eltoukhy

Chief Financial Officer

Derek Bertocci

Chief Legal Officer

Michael Wiley

Chief Medical Officer

Richard Lanman

COO & President

AmirAli Talasaz

VP of Marketing

Sandra Finley

Head of Sales

Stanley Welle

VP of Bioinformatics

Darya Chudova

Vice President, Pharma Business Development

Daniel Simon


Nasdaq Place (press release) - Oct, 31 2018

Guardant Health, Inc. (GH) moves -0.38% below SMA-50

Financial Times - Sep, 24 2017

DNA start-ups attract cash from venture funds

PR Newswire (press release) - Jun, 3 2017

Cure-One™ Announces Partnership with Guardant Health

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: